Bài giảng Hóa dược: Nhóm thuốc kháng sinh - Trường Đại Học Quốc Tế Hồng Bàng

<span class='text_page_counter'>(1)</span><div class='page_container' data-page=1>

<b>KHAÙNG SINH </b>



<b>-LACTAMIN (</b>



<b>-LACTAM) </b>

</div>
<span class='text_page_counter'>(2)</span><div class='page_container' data-page=2></div>
<span class='text_page_counter'>(3)</span><div class='page_container' data-page=3>

<b>CÁC THUỐC CHÍNH</b>

<b>Penicillin: </b>

<b>(PENAM) </b>

<b>penicillin G; penicillin V </b>

<b>methicillin; oxacillin </b>

<b>ampicillin; amoxicillin; </b>

<b>carbenicillin; ticarcillin </b>

<b>Ch</b>

<b>ấ</b>

<b>t </b>

<b>ứ</b>

<b>c ch</b>

<b>ế</b>



<b>-lactamase: </b>

<b>(OXAPENAM) </b>

<b> acid clavulanic </b>

<b>CARBAPENEM:</b>

<b> imipenem </b>

</div>
<span class='text_page_counter'>(4)</span><div class='page_container' data-page=4>

<b>CÁC THUỐC CHÍNH</b>

<b>Cephalosporin </b>

<b>(CEPHEM) </b>

<b>Thế hệ I : </b>

<b>cephalexin; cephalothin </b>

<b>Thế hệ II: </b>

<b>cefoxitin; cefaclor </b>

<b> </b>

<b>Thế hệ III: cefotaxime; cefoperazone; ceftriaxone </b>

<b> </b>

<b>Thế hệ IV: cefepime </b>

<b>Thế hệ V: ceftobiprole </b>

<b>MONOBACTAM</b>

<b>: </b>

<b>aztreonam </b>

N

O

S

</div>
<span class='text_page_counter'>(5)</span><div class='page_container' data-page=5></div>
<span class='text_page_counter'>(6)</span><div class='page_container' data-page=6>

<b>ME1036. ME1036 (CP5609; developed by Meiji Seika, licensed </b>

by Forest) is a broad-spectrum carbapenem that binds
with a high affinity to PBP 2a of MRSA (IC50 0.13 to 0.73
g/ml) and that <b>exhibits potent in vitro inhibitory </b>

<b>activity against MRSA </b>.

A series of 4-methyl carbapenems having structural similarity
to ME1036 showed potent activities against MRSA and PRSP, as
well as against the gram-negative organism ampicillin-resistant,
-lactamase-negative <i>Haemophilus influenzae</i>

N
HO

O

CO₂H
S

HN

NH

</div>
<span class='text_page_counter'>(7)</span><div class='page_container' data-page=7>

<b>PZ-601 (Razupenem). PZ-601 (formerly known as SMP- </b>

601; licensed from Dainippon Sumitomo Pharma Co., Ltd.,

Osaka, Japan) is a

<b>new carbapenem </b>

currently being developed

by Protez Pharmaceuticals (now Novartis) that has

demonstrated a

<b>high degree of potency against MRSA</b>

.

N
HO

O

CO₂H
S

HN

NH

</div>

<!--links-->